New insights into the pathogenesis of giant cell arteritis and hopes for the clinic

References

• Borchers AT, Gershwin ME. Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment. Autoimmun Rev 2012;11:A544-54
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009;61:1454-61
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Miranda-Filloy JA, Lopez-Diaz MJ, et al. Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study. Medicine 2007;86:61-8
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002;347:261-71
   PubMed Web of Science ®Google Scholar
• Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheumatism 2013;65:1-11
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 1998;41:1497-504
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine 2000;79:283-92
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA. Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions. Semin Arthritis Rheum 2004;33:289-93
   PubMed Web of Science ®Google Scholar
• Myklebust G, Gran JT. A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis. Br J Rheumatol 1996;35:1161-8
   PubMedGoogle Scholar
• Lie JT. Illustrated histopathologic classification criteria for selected vasculitis syndromes. American College of Rheumatology Subcommittee on Classification of Vasculitis. Arthritis Rheum 1990;33:1074-87
   PubMed Web of Science ®Google Scholar
• Bley TA, Uhl M, Carew J, et al. Diagnostic value of high-resolution MR imaging in giant cell arteritis. AJNR 2007;28:1722-7
   PubMed Web of Science ®Google Scholar
• Martinez-Lado L, Calvino-Diaz C, Pineiro A, et al. Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine 2011;90:186-93
   PubMed Web of Science ®Google Scholar
• Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009;68:318-23
   PubMed Web of Science ®Google Scholar
• Weyand CM, Goronzy JJ. Giant cell arteritis as an antigen-driven disease. Rheum Dis Clin North Am 1995;21:1027-39
   PubMed Web of Science ®Google Scholar
• Duhaut P, Bosshard S, Ducroix JP. Is giant cell arteritis an infectious disease? Biological and epidemiological evidence. Presse Med 2004;33:1403-8
   PubMed Web of Science ®Google Scholar
• Elling P, Olsson AT, Elling H. Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection. J Rheumatol 1996;23:112-19
   PubMed Web of Science ®Google Scholar
• Gabriel SE, Espy M, Erdman DD, et al. The role of parvovirus B19 in the pathogenesis of giant cell arteritis: a preliminary evaluation. Arthritis Rheum 1999;42:1255-8
   PubMed Web of Science ®Google Scholar
• Mitchell BM, Font RL. Detection of varicella zoster virus DNA in some patients with giant cell arteritis. Invest Ophthalmol Vis Sci 2001;42:2572-7
   PubMed Web of Science ®Google Scholar
• Haugeberg G, Bie R, Nordbo SA. Temporal arteritis associated with Chlamydia pneumoniae DNA detected in an artery specimen. J Rheumatol 2001;28:1738-9
   PubMed Web of Science ®Google Scholar
• Gordon LK, Goldman M, Sandusky H, et al. Identification of candidate microbial sequences from inflammatory lesion of giant cell arteritis. Clin Immunol 2004;111:286-96
   PubMed Web of Science ®Google Scholar
• Salvarani C, Gabriel SE, O’Fallon WM, Hunder GG. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med 1995;123:192-4
   PubMed Web of Science ®Google Scholar
• Petursdottir V, Johansson H, Nordborg E, Nordborg C. The epidemiology of biopsy-positive giant cell arteritis: special reference to cyclic fluctuations. Rheumatol (Oxford) 1999;38:1208-12
   PubMed Web of Science ®Google Scholar
• Bhatt AS, Manzo VE, Pedamallu CS, et al. In search of a candidate pathogen for giant cell arteritis: sequencing-based characterization of the giant cell arteritis microbiome. Arthritis Rheumatol 2014;66:1939-44
   PubMed Web of Science ®Google Scholar
• Weyand CM, Goronzy JJ. Immune mechanisms in medium and large-vessel vasculitis. Nat Rev Rheumatol 2013;9:731-40
   PubMed Web of Science ®Google Scholar
• Krupa WM, Dewan M, Jeon MS, et al. Trapping of misdirected dendritic cells in the granulomatous lesions of giant cell arteritis. Am J Pathol 2002;161:1815-23
   PubMed Web of Science ®Google Scholar
• Martinez-Taboada V, Brack A, Hunder GG, et al. The inflammatory infiltrate in giant cell arteritis selects against B lymphocytes. J Rheumatol 1996;23:1011-14
   PubMed Web of Science ®Google Scholar
• Cid MC, Campo E, Ercilla G, et al. Immunohistochemical analysis of lymphoid and macrophage cell subsets and their immunologic activation markers in temporal arteritis. Influence of corticosteroid treatment. Arthritis Rheum 1989;32:884-93
   PubMed Web of Science ®Google Scholar
• Banks PM, Cohen MD, Ginsburg WW, Hunder GG. Immunohistologic and cytochemical studies of temporal arteritis. Arthritis Rheum 1983;26:1201-7
   PubMed Web of Science ®Google Scholar
• Andersson R, Jonsson R, Tarkowski A, et al. T cell subsets and expression of immunological activation markers in the arterial walls of patients with giant cell arteritis. Ann Rheum Dis 1987;46:915-23
   PubMed Web of Science ®Google Scholar
• Regent A, Dib H, Ly KH, et al. Identification of target antigens of anti-endothelial cell and anti-vascular smooth muscle cell antibodies in patients with giant cell arteritis: a proteomic approach. Arthritis Res Ther 2011;13:R107
   PubMed Web of Science ®Google Scholar
• Baerlecken NT, Linnemann A, Gross WL, et al. Association of ferritin autoantibodies with giant cell arteritis/polymyalgia rheumatica. Ann Rheum Dis 2012;71:943-7
   PubMed Web of Science ®Google Scholar
• Thurner L, Preuss KD, Fadle N, et al. Progranulin antibodies in autoimmune diseases. J Autoimmun 2013;42:29-38
   PubMed Web of Science ®Google Scholar
• Regent A, Ly KH, Blet A, et al. Contribution of antiferritin antibodies to diagnosis of giant cell arteritis. Ann Rheum Dis 2013;72:1269-70
   PubMed Web of Science ®Google Scholar
• van der Geest KS, Abdulahad WH, et al. Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica. Arthritis Rheumatol 2014;66:1927-38
   PubMed Web of Science ®Google Scholar
• Bhatia A, Ell PJ, Edwards JC. Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis 2005;64:1099-100
   PubMed Web of Science ®Google Scholar
• Terrier B, Geri G, Chaara W, et al. Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis. Arthritis Rheum 2012;64:2001-11
   PubMed Web of Science ®Google Scholar
• Espigol-Frigole G, Corbera-Bellalta M, Planas-Rigol E, et al. Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis. Ann Rheum Dis 2013;72:1481-7
   PubMed Web of Science ®Google Scholar
• Samson M, Audia S, Fraszczak J, et al. Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum 2012;64:3788-98
   PubMed Web of Science ®Google Scholar
• Ciccia F, Rizzo A, Guggino G, et al. Difference in the expression of IL-9 and IL-17 correlates with different histological pattern of vascular wall injury in giant cell arteritis. Rheumatol (Oxford) 2015; In press
   Web of Science ®Google Scholar
• Kaplan MH. Th9 cells: differentiation and disease. Immunol Rev 2013;252:104-15
   PubMed Web of Science ®Google Scholar
• Carmona FD, Gonzalez-Gay MA, Martin J. Genetic component of giant cell arteritis. Rheumatology (Oxford) 2014;53:6-18
   PubMed Web of Science ®Google Scholar
• Carmona FD, Martin J, Gonzalez-Gay MA. Genetics of vasculitis. Curr Opin Rheumatol 2015;27:10-17
   PubMed Web of Science ®Google Scholar
• Marquez A, Hernandez-Rodriguez J, Cid MC, et al. Influence of the IL17A locus in giant cell arteritis susceptibility. Ann Rheum Dis 2014;73:1742-5
   PubMed Web of Science ®Google Scholar
• Marquez A, Solans R, Hernandez-Rodriguez J, et al. A candidate gene approach identifies an IL33 genetic variant as a novel genetic risk factor for GCA. PLoS One 2014(11):e113476
   Google Scholar
• Serrano A, Carmona FD, Castaneda S, et al. Evidence of association of the NLRP1 gene with giant cell arteritis. Ann Rheum Dis 2013;72:628-30
   PubMed Web of Science ®Google Scholar
• Serrano A, Marquez A, Mackie SL, et al. Identification of the PTPN22 functional variant R620W as susceptibility genetic factor for giant cell arteritis. Ann Rheum Dis 2013;72:1882-6
   PubMed Web of Science ®Google Scholar
• Choi YS, Choi HJ, Min JK, et al. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood 2009;114:3117-26
   PubMed Web of Science ®Google Scholar
• Enjuanes A, Benavente Y, Hernandez-Rodriguez J, et al. Association of NOS2 and potential effect of VEGF, IL6, CCL2 and IL1RN polymorphisms and haplotypes on susceptibility to GCA–a simultaneous study of 130 potentially functional SNPs in 14 candidate genes. Rheumatology (Oxford) 2012;51:841-51
   PubMed Web of Science ®Google Scholar
• Amoli MM, Garcia-Porrua C, Llorca J, et al. Endothelial nitric oxide synthase haplotype associations in biopsy-proven giant cell arteritis. J Rheumatol 2003;30:2019-22
   PubMed Web of Science ®Google Scholar
• Salvarani C, Casali B, Nicoli D, et al. Endothelial nitric oxide synthase gene polymorphisms in giant cell arteritis. Arthritis Rheum 2003;48:3219-23
   PubMed Web of Science ®Google Scholar
• Ciccia F, Alessandro R, Rizzo A, et al. IL-33 is overexpressed in the inflamed arteries of patients with giant cell arteritis. Ann Rheum Dis 2013;72(2):258-64
   PubMed Web of Science ®Google Scholar
• Deng J, Younge BR, Olshen RA, et al. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 2010;121:906-15
   PubMed Web of Science ®Google Scholar
• Hernandez-Rodriguez J, Segarra M, Vilardell C, et al. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford) 2004;43:294-301
   PubMed Web of Science ®Google Scholar
• Stanford SM, Bottini N. PTPN22: the archetypal non-HLA autoimmunity gene. Nat Rev Rheumatol 2014;10:602-11
   PubMed Web of Science ®Google Scholar
• Vang T, Liu WH, Delacroix L, et al. LYP inhibits T-cell activation when dissociated from CSK. Nat Chem Biol 2012;8:437-46
   PubMed Web of Science ®Google Scholar
• Zhang J, Zahir N, Jiang Q, et al. The autoimmune disease-associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. Nat Genet 2011;43:902-7
   PubMed Web of Science ®Google Scholar
• Zhong MC, Veillette A. Immunology: Csk keeps LYP on a leash. Nat Chem Biol 2012;8:412-13
   PubMed Web of Science ®Google Scholar
• Carmona FD, Mackie SL, Martin JE, et al. A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility. Am J Hum Genet 2015;96:565-80
   PubMed Web of Science ®Google Scholar
• Cortes A, Brown MA. Promise and pitfalls of the Immunochip. Arthrit Res Ther 2011;13:101
   PubMed Web of Science ®Google Scholar
• Saruhan-Direskeneli G, Hughes T, Aksu K, et al. Identification of multiple genetic susceptibility loci in Takayasu arteritis. Am J Hum Genet 2013;93:298-305
   PubMed Web of Science ®Google Scholar
• Viatte S, Plant D, Raychaudhuri S. Genetics and epigenetics of rheumatoid arthritis. Nat Rev Rheumatol 2013;9:141-53
   PubMed Web of Science ®Google Scholar
• Wang R, Kozhaya L, Mercer F, et al. Expression of GARP selectively identifies activated human FOXP3+ regulatory T cells. Proc Natl Acad Sci USA 2009;106:13439-13444
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Hajeer AH, Dababneh A, et al. Interferon-gamma gene microsatellite polymorphisms in patients with biopsy-proven giant cell arteritis and isolated polymyalgia rheumatica. Clin Exp Rheumatol 2004;22:S18-20
   PubMed Web of Science ®Google Scholar
• Cid MC, Corbera-Bellalta M, Terrades-García N, et al. Immunopathogenic mechanisms involved in giant-cell arteritis. Nephron 2015;129:39-41
   PubMedGoogle Scholar
• Rueda B, Lopez-Nevot MA, Lopez-Diaz MJ, et al. A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis. J Rheumatol 2005;32:1737-41
   PubMed Web of Science ®Google Scholar
• Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 2000;275:18138-44
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Hajeer AH, Dababneh A, et al. IL-6 promoter polymorphism at position -174 modulates the phenotypic expression of polymyalgia rheumatica in biopsy-proven giant cell arteritis. Clin Exp Rheumatol 2002;20:179-84
   PubMed Web of Science ®Google Scholar
• Piggott K, Biousse V, Newman NJ, et al. Vascular damage in giant cell arteritis. Autoimmunity 2009;42(7):596-604
   PubMed Web of Science ®Google Scholar
• Song GG, Choi SJ, Ji JD, Lee YH. Toll-like receptor polymorphisms and vasculitis susceptibility: meta-analysis and systematic review. Mol Biol Rep 2013;40:1315-23
   PubMed Web of Science ®Google Scholar
• Hilhorst M, Shirai T, Berry G, et al. T cell-macrophage interactions and granuloma formation in vasculitis. Front Immun 2014;5:432
   PubMed Web of Science ®Google Scholar
• Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007;146:621-30
   PubMed Web of Science ®Google Scholar
• Seror R, Baron G, Hachulla E, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis 2014;73:2074-81
   PubMed Web of Science ®Google Scholar
• De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986;45:136-8
   PubMed Web of Science ®Google Scholar
• Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002;46:1309-18
   PubMed Web of Science ®Google Scholar
• Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007;56:2789-97
   PubMed Web of Science ®Google Scholar
• Henes JC, Mueller M, Pfannenberg C, et al. Cyclophosphamide for large vessel vasculitis: assessment of response by PET/CT. Clin Exp Rheumatol 2011;29:S43-8
   PubMed Web of Science ®Google Scholar
• Loricera J, Blanco R, Hernandez JL, et al. Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients. Semin Arthritis Rheum 2015;44:717-23
   PubMed Web of Science ®Google Scholar
• Barr AJ. Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development. Future Med Chem 2010;2:1563-76
   PubMed Web of Science ®Google Scholar
• Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011;43:246-52
   PubMed Web of Science ®Google Scholar
• Ramasamy A, Curjuric I, Coin LJ, et al. A genome-wide meta-analysis of genetic variants associated with allergic rhinitis and grass sensitization and their interaction with birth order. J Allergy Clin Immunol 2011;128:996-1005
   PubMed Web of Science ®Google Scholar
• Chan DV, Somani AK, Young AB, et al. Signal peptide cleavage is essential for surface expression of a regulatory T cell surface protein, leucine rich repeat containing 32 (LRRC32). BMC Biochem 2011;12:27
   PubMed Web of Science ®Google Scholar
• Mattey DL, Hajeer AH, Dababneh A, et al. Association of giant cell arteritis and polymyalgia rheumatica with different tumor necrosis factor microsatellite polymorphisms. Arthritis Rheum 2000;43:1749-55
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, et al. Biopsy-negative giant cell arteritis: clinical spectrum and predictive factors for positive temporal artery biopsy. Semin Arthritis Rheum 2001;30:249-56
   PubMed Web of Science ®Google Scholar
• Civelek M, Lusis AJ. Systems genetics approaches to understand complex traits. Nat Rev Genet 2014;15:34-48
   PubMed Web of Science ®Google Scholar